Oser Communications Group
Palm Beach Sunday, April 28, 2019
AN INDEPENDENT PUBLICATION NOT AFFILIATED WITH NACDS
Grow Medical Supply Sales in a Hurry
Aurobindo Pharma Doubling Down on Capacity
An interview with Dave Palew, Director, U.S. Supply Chain, Aurobindo Pharma USA.
Prasco’s Generics Bring Affordability to Medications
An interview with Chris Arington, Chief Executive Officer, Prasco.
With a growing group of senior citizens in the United States, the demand for durable medical and mobility equipment continues to rise. And this group of senior citizens is the wealthiest this country has ever seen, resulting in an all-time high demand for quality and stylish equipment. These customers are shopping in retail stores and looking for products that meet their needs. Since the introduction of the HurryCane® on television in 2012, it has grown to be the No. 1 selling walking cane in the United States. The HurryCane highlights great features, such as standing on its own, the patented flex base that maintains contact with the ground for stability and folding for easy transport and storage. The HurryCane also comes in four great colors. These features, combined
DP: Ever-increasing customer needs require continuous expansion of our operations. Specifically, Aurobindo is investing in infrastructure in order to meet growing demand in the market. To this end, Aurobindo is increasing the size of its manufacturing facilities. In fact, our U.S. manufacturing facility is doubling in size to account for extended capacity to manufacture up to nine billion units of tablets/capsules annually in
CA: The prescription drug landscape continues to evolve and authorized generics have become an increasingly important tool for pharmaceutical companies. Authorized generics are a unique class of generics with the exact same drug product as the brand, and they represent a meaningful option for a patient to access a brand quality product at an affordable price. Prasco continues to have a leadership position in this space – in the past three years, we have launched authorized generic versions of brand products
BOOTH #540
BOOTH #444
BOOTH #224
Continued on Page 37
CDD: How is Aurobindo positioned to continually increase its capacity with market demands?
Continued on Page 37
LUMIFY Eye Drops Brightening Skincare for Eye Care Category for Retailers Today’s Customer Bausch + Lomb LUMIFY® redness reliever eye drops are continuing to brighten the eye care aisle in more ways than one. Since launching 10 months ago, this 2018 NACDS TSE Product Showcase Award winner has already achieved the No. 1 dollar share among redness relievers, awakening a once sleepy category to more than 25 percent growth. Backed by six clinical studies, LUMIFY has a strong efficacy and safety profile with a low risk for rebound redness when used as directed and 95 percent symptom improvement seen at one minute and lasting up to eight hours. With these results, it’s not surprising that LUMIFY is also already the No. 1 eye doctor recommended redness reliever brand.
With seemingly endless growth in skincare products, new Remedy Dermatology Series Moisturizing Lotion has key elements that make it appealing to today’s wellinformed consumer. First, it appeals to their search for gentle, more natural options. The formula is rich in gentle botanicals like blue-green algae, soy proteins, green tea and clove flower extracts. These plant-derived ingredients provide multiple skin benefits, including humectants, moisturizers, skin nutrients and soothing antioxidants. Together, Remedy Dermatology Series provides a complete level of skin support that “hydrates while maintaining skin’s natural defenses.”
BUNGALOW #12
BOOTH #532
Continued on Page 37
Continued on Page 33
CDD: Why does it seem like every day another authorized generic is launching?
Continued on Page 37
Ascensia Aims to Improve Lives of Those with Diabetes
According to figures from the American Diabetes Association, there are 30 million people living with diabetes in the United States, and 84 million people estimated to have prediabetes or at risk of developing Type 2 diabetes. The total cost of it has been calculated as $322 billion and those patients spend 2.3 times more with healthcare cost than those without diabetes (American Diabetes Association, Statistics About Diabetes, www.diabetes.org/diabetes-basics/statistics, accessed January 2019). Overall in the United States, healthcare spend is growing at a faster pace than inflation, and the wages for workers are not able to keep up with this increase.
BOOTH #6
Continued on Page 37